Skip to main content

A Study to Evaluate Patient Satisfaction With the Overall Face and Neck Appearance After Combined Treatment of OnabotulinumtoxinA, JUVÉDERM® Products, KYBELLA, CoolSculpting Elite and SkinMedica Products

Completed · Phase 4 · NCT06783621

Conditions: Facial Contouring

At a glance

Research payments reported, 2025
$799,791
U.S. investigators named
10
Sites paid
10
Planned or actual enrollment
130

About the trial

Sponsor
AbbVie
Tested
OnabotulinumtoxinA (drug), JUVÉDERM (device), CoolSculpting Elite System (device), SkinMedica Products (other), KYBELLA (drug)
Dates
Started 2025-01-16; completion 2026-03-20
Results posted
Not yet

A study to evaluate overall participant satisfaction of face and neck appearance after treatment with onabotulinumtoxinA, JUVÉDERM® products, KYBELLA, CoolSculpting Elite, and select SkinMedica products in a diverse population.

From ClinicalTrials.gov, last updated 2026-05-22. Full record, eligibility and contacts (opens in a new tab)

Industry funding

AbbVie Inc. reported $799,791 in research payments for this study in 2025 (103 payments).

Products named: Botox

Research payments usually go to hospitals, universities and research sites to run a study, not to the investigators personally. A payment is not evidence of wrongdoing.

U.S. investigators named on this study

Clinicians the company named as principal investigators in its Open Payments reports.

Sites paid to run it

  • Delricht LLC $109,749
  • Bellaire Dermatology Associates $104,079
  • Pacific Clinical Innovations Inc $96,376
  • Skin Dc PLLC $82,451
  • Charles M Boyd MD PLLC $80,090
  • Keith A Marcus MD Inc $72,373
  • Luxurgery LLC $70,507
  • Center for Dermatology $68,175
  • Jeunesse Medispa PA $59,982
  • Skin Research Institute LLC $56,010

Sources: CMS Open Payments research payments (program year 2025) and ClinicalTrials.gov, U.S. National Library of Medicine.